ArticleJournal of inflammation research2026
Diagnostic Value and Mechanism of Action of LINC00641 in Sepsis-Associated Acute Kidney Injury.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sepsis-associated acute kidney injury (SAKI) has a rapid onset and carries serious risks. Long non-coding RNAs (lncRNAs) appear to have a key role in SAKI pathogenesis. The goal of this study is to explore the expression and molecular mechanisms of LINC00641 in patients with SAKI. Patients and Methods: Clinical data between SAKI and sepsis-only patients were compared using analysis of variance. Serum LINC00641 and miR-485-5p levels were measured by qRT-PCR. The predictive value of LINC00641 for SAKI was evaluated with ROC curves. Cell Counting Kit-8, flow cytometry, qRT-PCR and enzyme-linked immunosorbent assay were used to assess cell proliferation, apoptosis, apoptosis-related mRNA, and inflammatory factor level. Dual luciferase and RNA immunoprecipitation assays were used to validate the LINC00641-miR-485-5p interaction. Results: SAKI patients exhibited significantly elevated serum levels of LINC00641 compared to non-SAKI patients. The ROC analysis confirmed that LINC00641 possesses strong diagnostic potential for SAKI. Reducing LINC00641 expression mitigated LPS-induced damage to renal epithelial cells, marked by enhanced cell proliferation, reduced apoptosis, and lower levels of IL-6 and TNF-α. In SAKI patients, serum miR-485-5p levels were inverse linked to LINC00641 expression. Suppression of miR-485-5p expression abrogated the protective benefits of reduced LINC00641 expression on renal epithelial cell injury. Conclusion: Elevated serum expression of LINC00641 is tightly linked to the emergence and progression of SAKI. By modulating the expression of miR-485-5p, LINC00641 influences LPS-induced renal epithelial cell injury, suggesting a novel therapeutic target for SAKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.